<DOC>
	<DOC>NCT02826603</DOC>
	<brief_summary>Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.</brief_summary>
	<brief_title>Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Subjects must give a written, signed and dated informed consent Chronic plaquetype psoriasis present for at least 6 months before randomization Moderate to severe plaque psoriasis as defined at randomization by: PASI score of ≥12 and Body Surface Area (BSA) affected by plaquetype psoriasis ≥10% and IGA mod 2011 ≥3 (based on a scale of 04) Candidate for systemic therapy, defined as having psoriasis inadequately controlled by: Topical treatment (including topical corticosteroids) and/or Phototherapy and/or Previous systemic therapy Forms of psoriasis other than plaque psoriasis Druginduced psoriasis Ongoing use of prohibited treatments Previous exposure to secukinumab or any other biologic drug directly targeting IL17A or IL17RA, or ustekinumab, or any therapies targeting IL12 or IL23 Use of any other investigational drugs within 5 halflives of the investigational treatment before study drug initiation Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Plaque psoriasis,</keyword>
	<keyword>secukinumab,</keyword>
	<keyword>ustekinumab</keyword>
</DOC>